Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kura Oncology ( (KURA) ) has shared an update.
On June 12, 2025, Kura Oncology and Kyowa Kirin announced positive results from the KOMET-007 Phase 1a/1b trial of ziftomenib in combination with standard chemotherapy for newly diagnosed AML patients with NPM1-m and KMT2A-r mutations. The trial demonstrated high rates of complete remission and minimal residual disease negativity, with a favorable safety profile. This development positions Kura Oncology to advance to Phase 3 studies, potentially impacting its market position and offering new hope for AML patients.
The most recent analyst rating on (KURA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Kura Oncology stock, see the KURA Stock Forecast page.
Spark’s Take on KURA Stock
According to Spark, TipRanks’ AI Analyst, KURA is a Neutral.
Kura Oncology faces challenges typical of biotech firms in transition, with positive revenue growth yet struggling profitability. Significant milestones in drug applications and a strong cash position are positive, but technical indicators and valuation metrics present caution. The company’s stock performance reflects these mixed factors.
To see Spark’s full report on KURA stock, click here.
More about Kura Oncology
Kura Oncology, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment. The company’s primary product is ziftomenib, an investigational menin inhibitor targeting acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as NPM1-m and KMT2A-r.
Average Trading Volume: 1,284,983
Technical Sentiment Signal: Sell
Current Market Cap: $561.9M
For an in-depth examination of KURA stock, go to TipRanks’ Overview page.